Bocchia, Monica <br/><br/>
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients.  [electronic resource] 

 -  Oncotarget  Nov 2016 
 - 72311-72321 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article 
<br/><br/><label>ISSN: </label>1949-2553 
<br/><br/><label>Standard No.: </label>10.18632/oncotarget.11100  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Agents--therapeutic use<br/>Atherosclerosis--blood<br/>Cross-Sectional Studies<br/>Cytokines--blood<br/>Dyslipidemias--blood<br/>Female<br/>Genetic Predisposition to Disease<br/>Humans<br/>Imatinib Mesylate--therapeutic use<br/>Incidence<br/>Inflammation--chemically induced<br/>Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy<br/>Male<br/>Middle Aged<br/>Oxidation-Reduction--drug effects<br/>Polymorphism, Single Nucleotide<br/>Prospective Studies<br/>Protein Kinase Inhibitors--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Retrospective Studies<br/>Risk Factors<br/>Scavenger Receptors, Class E--genetics<br/>Thrombosis--blood